Health Condition 1: null- Eczema of skin
Conditions
Interventions
Intervention1: Steroneo Skin Cream: 30gm of Physalis Angulata Supercritical Extract used topically twice a day
Sponsors
Rehmat Clinic
Eligibility
Inclusion criteria
Inclusion criteria: Clinically diagnosed with eczematous lesions of any of the following types and requiring mild to moderate topical steroid therapy: • Atopic dermatitis • Contact dermatitis • Xerotic eczema • Nodular eczema • Seborrheic dermatitis • Neurocutaneous dermatitis (lichen simplex chronicus) • Drug eruptions, photo-dermatitis • Pruritus requiring topical corticosteroids Patients/parents who sign the written informed consent form Patients willing to and able to understand and comply with all study requirements
Exclusion criteria
Exclusion criteria: 1. Patients having any of the following conditions: • Lichen planus • Severe dermatitis requiring systemic corticosteroids • Infantile dermatitis 2. Patients requiring systemic corticosteroids on any form 3. Pregnant and lactating women 4. Patients with known hypersensitivity to any of the ingredients/excipients of the study cream 5. Any other condition, which in the opinion of the clinician/investigator, could interfere significantly with the treatment and assessment process 6. Use of any investigational therapy within 30 days prior to randomization 7. Patients not willing to provide written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the efficacy of Steroneo Physalis Angulata Supercritical Extract application for treatment of eczematous lesions.Timepoint: 12 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Dermatology Life Quality Index would be assessed using a 10 item questionnaire by patients above 16 years of age Reduction in number and size of lesions of eczema. Appearance of new lesions of eczema. Pruritus Score will be assessed on a scale of 0 to 3. Erythema will be assessed on a scale of 0 to 3. Global assessment of response to therapy evaluated by the doctors on a 5point scale. Global assessment of tolerability to therapy would be assessed by the patients on a 5point scale. Timepoint: 12 weeks | — |
Countries
India
Contacts
Public ContactRashid Shaikh
Rehmat Clinic
Outcome results
None listed